

E-PHA BINDING TO GLYCOPROTEINS FROM SERUM OF CDGS PATIENTS




1. Control
2. Type 1a--died at 6
3. Type 1a--living
4. Type 4
5. Type 1b--before mannose
6. Type 1b--after mannose

Status: E-PHA binding may indicate clinical severity in Type 1a patients.
Further analyses pending.

Figure 1

A




B

Normal Human blood

CDGS Type II blood

E-PHA

A) Flow cytometry and B) dot-blot analyses on blood from normal and CDGS Type II patient.



B




Figure 3





Figure 4

A



B

Normal blood

Core 2 GlcNAc-T deficient mouse blood

B220

1B11

Figure 5




FIGURE 6

Core fucosylation of serum immunoglobulin M
before and after initiation of fucose therapy






Figure 7

**FIGURE 8**




Figure 9





FIGURE 10

**Figure 11**





Figure 12

**FIGURE 13**




Figure 14




FIGURE 15







Figure 17



	Binding of Diagnostic Reagent	
	Normal	Glycosylation Disorder
	+	-
	-	+